192 related articles for article (PubMed ID: 35733032)
21. A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.
Bairey O; Lebel E; Buxbaum C; Porges T; Taliansky A; Gurion R; Goldschmidt N; Shina TT; Zektser M; Hofstetter L; Siegal T
Hematol Oncol; 2023 Dec; 41(5):838-847. PubMed ID: 37403752
[TBL] [Abstract][Full Text] [Related]
22. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
[TBL] [Abstract][Full Text] [Related]
23. [Clinical Efficacy of High Dose Methotrexate, Temozolomide and Rituximab in the Treatment of Patients with Primary Central Nervous System Lymphoma].
Pang DW; Chen FL; Guo HG; Jiang XM; Wei XJ; Liu SC; Huang L; Liang ZL; Li WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1175-1180. PubMed ID: 34362499
[TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of completion of initial high-dose methotrexate therapy on primary central nervous system lymphoma: a single institution experience.
Makino K; Nakamura H; Hide T; Kuroda J; Yano S; Kuratsu J
Int J Clin Oncol; 2015 Feb; 20(1):29-34. PubMed ID: 24722885
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
Han X; Ji Y; Ouyang M; Zhu T; Zhou D
Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
[TBL] [Abstract][Full Text] [Related]
26. High-dose methotrexate dosing strategy in primary central nervous system lymphoma.
Wang A; Cirrone F; De Los Reyes FA; Papadopoulos J; Saint Fleur-Lominy S; Xiang E
Leuk Lymphoma; 2022 Jun; 63(6):1348-1355. PubMed ID: 35120432
[TBL] [Abstract][Full Text] [Related]
27. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.
Kasenda B; Ferreri AJ; Marturano E; Forst D; Bromberg J; Ghesquieres H; Ferlay C; Blay JY; Hoang-Xuan K; Pulczynski EJ; Fosså A; Okoshi Y; Chiba S; Fritsch K; Omuro A; O'Neill BP; Bairey O; Schandelmaier S; Gloy V; Bhatnagar N; Haug S; Rahner S; Batchelor TT; Illerhaus G; Briel M
Ann Oncol; 2015 Jul; 26(7):1305-13. PubMed ID: 25701456
[TBL] [Abstract][Full Text] [Related]
28. Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.
Kobayashi H; Yamaguchi S; Motegi H; Kaneko S; Endou S; Onimaru R; Terasaka S; Houkin K
J Chemother; 2019 Feb; 31(1):35-41. PubMed ID: 30773132
[TBL] [Abstract][Full Text] [Related]
29. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
30. Monotherapy with methotrexate for primary central nervous lymphoma has single agent activity in the absence of radiotherapy: a single institution cohort.
Cobert J; Hochberg E; Woldenberg N; Hochberg F
J Neurooncol; 2010 Jul; 98(3):385-93. PubMed ID: 20020180
[TBL] [Abstract][Full Text] [Related]
31. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
32. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma.
Chamberlain MC; Johnston SK
Neuro Oncol; 2010 Jul; 12(7):736-44. PubMed ID: 20511181
[TBL] [Abstract][Full Text] [Related]
33. A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma.
Taoka K; Okoshi Y; Sakamoto N; Takano S; Matsumura A; Hasegawa Y; Chiba S
Int J Hematol; 2010 Nov; 92(4):617-23. PubMed ID: 20967518
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
[TBL] [Abstract][Full Text] [Related]
35. Outcome of Primary Central Nervous System Lymphoma Treated with Combined Surgical Resection and High- Dose Methotrexate Chemotherapy: A Single-Institution Retrospective Study.
Zhang Q; Wang DW; Shu HS
Turk Neurosurg; 2022; 32(1):1-5. PubMed ID: 35018626
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
Wang Y; Liu B; Xu D; Zhao H; Zhu Y; Xu J; Tao R
Neurol India; 2013; 61(3):260-4. PubMed ID: 23860145
[TBL] [Abstract][Full Text] [Related]
37. Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
Correa DD; Shi W; Abrey LE; Deangelis LM; Omuro AM; Deutsch MB; Thaler HT
Neuro Oncol; 2012 Jan; 14(1):101-8. PubMed ID: 22013168
[TBL] [Abstract][Full Text] [Related]
38. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
39. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
[TBL] [Abstract][Full Text] [Related]
40. Urine volume to hydration volume ratio is associated with pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma.
Isono T; Hira D; Morikochi A; Fukami T; Ueshima S; Nozaki K; Terada T; Morita SY
Pharmacol Res Perspect; 2021 Dec; 9(6):e00883. PubMed ID: 34664791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
